Thromb Haemost 1991; 65(03): 275-279
DOI: 10.1055/s-0038-1648134
Original Article
Schattauer GmbH Stuttgart

Correlation between Baseline Plasminogen Activator Inhibitor Levels and Clinical Outcome during Therapy with Tissue Plasminogen Activator for Acute Myocardial Infarction

David C Sane
The Division of Cardiology, Department of Medicine, Duke University, Durham, NC; the Departments of Medicine and Biochemistry, University of Vermont, Burlington, VT; the Division of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor; Christ Hospital, Cincinnati; the Riverside Methodist Hospital, Columbus; and the Center for Thrombosis and Vascular Research, University of Leuven, Belgium
,
David C Stump
The Division of Cardiology, Department of Medicine, Duke University, Durham, NC; the Departments of Medicine and Biochemistry, University of Vermont, Burlington, VT; the Division of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor; Christ Hospital, Cincinnati; the Riverside Methodist Hospital, Columbus; and the Center for Thrombosis and Vascular Research, University of Leuven, Belgium
,
Eric J Topol
The Division of Cardiology, Department of Medicine, Duke University, Durham, NC; the Departments of Medicine and Biochemistry, University of Vermont, Burlington, VT; the Division of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor; Christ Hospital, Cincinnati; the Riverside Methodist Hospital, Columbus; and the Center for Thrombosis and Vascular Research, University of Leuven, Belgium
,
Kristina N Sigmon
The Division of Cardiology, Department of Medicine, Duke University, Durham, NC; the Departments of Medicine and Biochemistry, University of Vermont, Burlington, VT; the Division of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor; Christ Hospital, Cincinnati; the Riverside Methodist Hospital, Columbus; and the Center for Thrombosis and Vascular Research, University of Leuven, Belgium
,
Dean J Kereiakes
The Division of Cardiology, Department of Medicine, Duke University, Durham, NC; the Departments of Medicine and Biochemistry, University of Vermont, Burlington, VT; the Division of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor; Christ Hospital, Cincinnati; the Riverside Methodist Hospital, Columbus; and the Center for Thrombosis and Vascular Research, University of Leuven, Belgium
,
Barry S George
The Division of Cardiology, Department of Medicine, Duke University, Durham, NC; the Departments of Medicine and Biochemistry, University of Vermont, Burlington, VT; the Division of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor; Christ Hospital, Cincinnati; the Riverside Methodist Hospital, Columbus; and the Center for Thrombosis and Vascular Research, University of Leuven, Belgium
,
Susan J Mantell
The Division of Cardiology, Department of Medicine, Duke University, Durham, NC; the Departments of Medicine and Biochemistry, University of Vermont, Burlington, VT; the Division of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor; Christ Hospital, Cincinnati; the Riverside Methodist Hospital, Columbus; and the Center for Thrombosis and Vascular Research, University of Leuven, Belgium
,
Elizabeth Macy
The Division of Cardiology, Department of Medicine, Duke University, Durham, NC; the Departments of Medicine and Biochemistry, University of Vermont, Burlington, VT; the Division of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor; Christ Hospital, Cincinnati; the Riverside Methodist Hospital, Columbus; and the Center for Thrombosis and Vascular Research, University of Leuven, Belgium
,
Désiré Collen
The Division of Cardiology, Department of Medicine, Duke University, Durham, NC; the Departments of Medicine and Biochemistry, University of Vermont, Burlington, VT; the Division of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor; Christ Hospital, Cincinnati; the Riverside Methodist Hospital, Columbus; and the Center for Thrombosis and Vascular Research, University of Leuven, Belgium
,
Robert M Califf
The Division of Cardiology, Department of Medicine, Duke University, Durham, NC; the Departments of Medicine and Biochemistry, University of Vermont, Burlington, VT; the Division of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor; Christ Hospital, Cincinnati; the Riverside Methodist Hospital, Columbus; and the Center for Thrombosis and Vascular Research, University of Leuven, Belgium
› Author Affiliations
Further Information

Publication History

Received: 07 June 1990

Accepted after revision 06 October 1990

Publication Date:
02 July 2018 (online)

Summary

Baseline plasminogen activator inhibitor (PAI) levels were examined for their influence on the responses to thrombolysis with recombinant tissue plasminogen activator (rt-PA) administered for acute myocardial infarction during the Thrombolysis and Myocardial Infarction (TAMI)-I study. Baseline PAI activity was 19 ± 21 IU/ml (normal <5 IU/ml) and baseline PAI-1 antigen 54 ± 53 ng/ml (normal 27 ± 16 ng/ml), confirming previous findings of elevated PAI levels during acute myocardial infarction. Among clinical outcomes, lower PAI-1 antigen levels correlated weakly with greater patency at the 90 min angiogram. Thus, high baseline plasma PAI-1 levels may be detrimental to reperfusion with t-PA. There was no correlation with other major in-hospital clinical outcomes including reocclusion at the 7-10 day angiogram, survival to discharge, or bleeding. During the follow up period of 2.0 ± 0.4 years, no relationship between baseline PAI levels and post-discharge reinfarction was observed.